<DOC>
	<DOCNO>NCT00082940</DOCNO>
	<brief_summary>RATIONALE : Biological therapy , denileukin diftitox , may interfere growth cancer cell slow growth chronic lymphocytic leukemia . PURPOSE : This phase II trial study well denileukin diftitox work treat patient fludarabine-refractory B-cell chronic lymphocytic leukemia .</brief_summary>
	<brief_title>Denileukin Diftitox Treating Patients With Fludarabine-Refractory B-Cell Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine complete partial response rate patient fludarabine-refractory B-cell chronic lymphocytic leukemia treat denileukin diftitox . Secondary - Determine toxicity profile drug patient . - Determine response rate patient ( regardless CD25 receptor density ) treat drug . - Determine progression-free survival overall survival patient treated drug . OUTLINE : This multicenter study . Patients receive denileukin diftitox IV 1 hour day 1-5 . Treatment repeat every 21 day 8 course absence disease progression unacceptable toxicity . Patients achieve complete response 8 course proceed follow-up . Patients achieve partial response stable disease 8 course may continue treatment discretion investigator . Patients follow every 3 month 1 year annually relapse . PROJECTED ACCRUAL : A total 12-44 patient accrue study within 1 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Denileukin diftitox</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis Bcell chronic lymphocytic leukemia ( CLL ) meeting follow criterion time course disease ( e.g. , initial diagnosis relapse ) : Absolute lymphocytosis &gt; 5,000/mm^3 Lymphocytes must appear mature &lt; 55 % prolymphocytes More 30 % nucleated cell lymphoid bone marrow aspirate smear Lymphoid infiltrate compatible bone marrow involvement CLL core bone marrow biopsy Predominant Bcell monoclonal population cell share Bcell marker ( CD19 ) CD5 antigen absence panTcell marker lymphocyte immunophenotyping Highrisk disease OR intermediaterisk disease Patients intermediaterisk group must evidence active disease demonstrate least 1 follow criterion : Massive progressive splenomegaly and/or adenopathy Weight loss &gt; 10 % within past 6 month Common toxicity grade 24 fatigue Fevers &gt; 100.5°F OR night sweat 2 week without evidence infection Progressive lymphocytosis increase &gt; 50 % 2month period anticipate doubling time &lt; 6 month Failed least 1 prior fludarabine regimen , define 1 follow criterion : Refractory intolerant fludarabine Relapsed within 6 month completion fludarabine No CNS leukemia No mantle cell lymphoma leukemic phase PATIENT CHARACTERISTICS : Age 18 Performance status Zubrod 02 Life expectancy More 2 month Hematopoietic Absolute neutrophil count ≥ 1,000/mm^3 Platelet count ≥ 50,000/mm^3 Hemoglobin ≥ 8 g/dL ( transfusion allow ) Hepatic Albumin ≥ 3 g/dL AST ALT ≤ 2.5 time upper limit normal ( ULN ) Bilirubin ≤ 1.5 time ULN No hepatitis B C infection Renal Creatinine ≤ 1.5 mg/dL OR Creatinine clearance ≥ 40 mL/min Cardiovascular LVEF ≥ 40 % Other No uncontrolled infection No concurrent serious illness No HIV infection Not pregnant nursing Negative pregnancy test Fertile patient must use two effective method contraception ( one must nonhormonal ) least 1 month study participation PRIOR CONCURRENT THERAPY : Biologic therapy Prior denileukin diftitox allow Chemotherapy See Disease Characteristics Endocrine therapy No concurrent corticosteroid antiemetic Radiotherapy No concurrent radiotherapy Surgery Not specify Other At least 28 day since prior anticancer therapy recover No concurrent antineoplastic drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>B-cell chronic lymphocytic leukemia</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
</DOC>